Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The early assessment of new drugs for Alzheimer's disease remains difficult because of the
lack of predictive end-point. The use of a battery including different parameters could
improve this early development of new drugs. Nevertheless, the interest of such a battery
should previously be validated with the yet marketed AD drugs